argenx SE
ARGX614.760USD
+14.250+2.37%
Close 04/25, 16:00（ET）Quotes delayed by 15 min
37.35BMarket Cap
44.84P/E TTM
More Details of argenx SE Company
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Company Info
Company codeARGX
Company nameargenx SE
IPO dateJul 10, 2014
Founded at2008
CEOMr. Tim van Hauwermeiren
Number of employees1599
Security typeOrdinary Share
Fiscal year-endJul 10
AddressLaarderhoogtweg 25
CityAMSTERDAM
Stock exchangeEuronext Brussels
CountryNetherlands
Postal code1101 EB
Phone31763030
Websitehttps://www.argenx.com/
Company codeARGX
IPO dateJul 10, 2014
Founded at2008
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
500.00
--
Mrs. Camilla Sylvest
Mrs. Camilla Sylvest
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Ana Cespedes
Dr. Ana Cespedes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Karen Massey
Ms. Karen Massey
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Joseph Donald (Don) debethizy, Ph.D.
Dr. Joseph Donald (Don) debethizy, Ph.D.
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mrs. Andria Wilk
Mrs. Andria Wilk
Global Head of Quality
Global Head of Quality
--
--
Mr. Arjen Lemmen
Mr. Arjen Lemmen
Vice President - Corporate Development and Strategy
Vice President - Corporate Development and Strategy
--
--
Ms. Malini Moorthy
Ms. Malini Moorthy
General Counsel
General Counsel
--
--
Mr. Peter Ulrichts
Mr. Peter Ulrichts
Chief Scientific Officer
Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
500.00
--
Mrs. Camilla Sylvest
Mrs. Camilla Sylvest
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Ana Cespedes
Dr. Ana Cespedes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Karen Massey
Ms. Karen Massey
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Joseph Donald (Don) debethizy, Ph.D.
Dr. Joseph Donald (Don) debethizy, Ph.D.
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
United States
1.90B
86.56%
Rest of the World
161.25M
7.36%
Japan
89.39M
4.08%
China
43.52M
1.99%
Netherlands
153.00K
0.01%
By Business
By Region
No Data
Shareholder
Update time: Sat, Apr 26
Update time: Sat, Apr 26
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Fidelity Management & Research Company LLC
8.87%
T. Rowe Price Associates, Inc.
7.71%
Artisan Partners Limited Partnership
5.03%
Janus Henderson Investors
3.79%
Capital World Investors
2.93%
Other
71.66%
Shareholder Statistics
Shareholder
Proportion
Fidelity Management & Research Company LLC
8.87%
T. Rowe Price Associates, Inc.
7.71%
Artisan Partners Limited Partnership
5.03%
Janus Henderson Investors
3.79%
Capital World Investors
2.93%
Other
71.66%
Type
Shareholder
Proportion
Investment Advisor
32.37%
Investment Advisor/Hedge Fund
17.27%
Hedge Fund
4.50%
Research Firm
1.80%
Pension Fund
0.51%
Private Equity
0.42%
Bank and Trust
0.06%
Other
43.06%
Institutional Shareholding
Update time: Sun, Jan 19
Update time: Sun, Jan 19
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
760
34.67M
56.84%
-3.53M
2024Q4
769
34.65M
57.94%
-3.60M
2024Q3
721
35.68M
59.67%
-2.04M
2024Q2
693
34.77M
58.16%
-2.15M
2024Q1
675
34.54M
58.16%
-754.92K
2023Q4
655
33.23M
56.14%
-574.05K
2023Q3
612
32.76M
56.24%
+237.83K
2023Q2
559
31.23M
55.80%
-1.48M
2023Q1
539
31.55M
56.67%
-1.67M
2022Q4
531
31.27M
56.45%
-2.84M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
5.41M
8.87%
+798.29K
+17.31%
Dec 31, 2024
T. Rowe Price Associates, Inc.
4.70M
7.71%
-292.11K
-5.85%
Dec 31, 2024
Artisan Partners Limited Partnership
3.07M
5.03%
-443.25K
-12.62%
Dec 31, 2024
Janus Henderson Investors
2.31M
3.79%
-166.85K
-6.73%
Dec 31, 2024
Capital World Investors
1.79M
2.93%
+86.69K
+5.10%
Dec 31, 2024
Avoro Capital Advisors LLC
1.24M
2.03%
--
--
Dec 31, 2024
T. Rowe Price International Ltd
813.71K
1.33%
-11.54K
-1.40%
Dec 31, 2024
RTW Investments L.P.
673.50K
1.1%
+19.07K
+2.91%
Dec 31, 2024
ClearBridge Investments, LLC
629.83K
1.03%
+40.33K
+6.84%
Dec 31, 2024
Bellevue Asset Management AG
593.18K
0.97%
-39.65K
-6.26%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
Tema Neuroscience and Mental Health ETF
4.99%
VanEck Biotech ETF
4.9%
iShares Neuroscience and Healthcare ETF
4.31%
iShares Health Innovation Active ETF
3.47%
First Trust NYSE Arca Biotechnology Index Fund
2.96%
Goldman Sachs Future Health Care Equity ETF
2.4%
iShares Biotechnology ETF
2.32%
PGIM Jennison International Opportunities ETF
2.07%
Invesco Nasdaq Biotechnology ETF
1.93%
Harbor Health Care ETF
1.93%
View more
Tema Neuroscience and Mental Health ETF
Proportion4.99%
VanEck Biotech ETF
Proportion4.9%
iShares Neuroscience and Healthcare ETF
Proportion4.31%
iShares Health Innovation Active ETF
Proportion3.47%
First Trust NYSE Arca Biotechnology Index Fund
Proportion2.96%
Goldman Sachs Future Health Care Equity ETF
Proportion2.4%
iShares Biotechnology ETF
Proportion2.32%
PGIM Jennison International Opportunities ETF
Proportion2.07%
Invesco Nasdaq Biotechnology ETF
Proportion1.93%
Harbor Health Care ETF
Proportion1.93%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data